Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002

Published:2014-01-15 Issue:1 Volume:165 Page:102-111
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Rizzieri David A.¹,Johnson Jeffrey L.²,Byrd John C.³,Lozanski Gerard⁴,Blum Kristie A.³,Powell Bayard L.⁵,Shea Thomas C.⁶,Nattam Sreenivasa⁷,Hoke Eva²,Cheson Bruce D.⁸,Larson Richard A.⁹,

Affiliation:

1. Department of Medicine; Duke University Medical Center; Durham NC USA

2. Alliance Statistical and Data Center; Duke University Medical Center; Durham NC USA

3. Division of Hematology; The Ohio State University; Columbus OH USA

4. Department of Pathology; The Ohio State University; Columbus OH USA

5. Wake Forest University; Winston Salem NC USA

6. University of North Carolina; Chapel Hill NC USA

7. Fort Wayne Medical Oncology & Hematology; Fort Wayne IN USA

8. Georgetown University Hospital; Washington DC USA

9. University of Chicago; Chicago IL USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12736/fullpdf

Reference34 articles.

1. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study;Advani;Journal of Clinical Oncology,2010

2. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis;Barnes;Annals of Onocology,2011

3. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

4. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma;Corazzelli;British Journal of Haematology,2012

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation;The Oncologist;2024-02-10

2. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia;Annals of Oncology;2024-01

3. Diagnosis and Treatment of Burkitt Lymphoma in Adults: Clinical Practice Guidelines from ERN-EuroBloodNet "Recommendations Carried Out within the Framework of European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 10108571. ERN-EuroBloodNet is Partly Co-Funded by the European Union within the Framework of the Fourth EU Health Programme";2024

4. Burkitt's Lymphoma;Comprehensive Hematology and Stem Cell Research;2024

5. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial;The Lancet Haematology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3